First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD)Completed enrollment for Cohort 2 (mucosal healing) of Phase 1b ANB033 trial in CeD; top-line data anticipated in Q1 2027Anticipate initiating late-stage clinical trial for ANB033 in CeD in 2027Enrollment ongoing for Phase 1b ANB033 trial in eosinophilic esophagitis; top-line data anticipated in Q3 2027Anticipate initiating Phase 2 development of ANB033 in vitiligo and one additional indication in H1 2027Completed private placement with $200 million in gross proceeds; pro